email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Editorial(ISSN: 2638-5945)

Epigenetically Reprogrammed Methylation as a Gifted Potential Cancer Biomarker

Volume 3 - Issue 2

Seyed Mohammad Kazem Aghamir, Maryam Aghaii and Fatemeh Khatami*

  • Author Information Open or Close
    • Urology Research Center, Tehran University of Medical Sciences, Iran

    *Corresponding author: Fatemeh Khatami, Urology Research Center, Sina Hospital, Hassan Abad Square, Tehran, Iran

Received: September 24, 2019;   Published: September 30, 2019

DOI: 10.32474/OAJOM.2019.03.000156

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Ontrary to genetic changes of DNA molecule which change exactly the sequence of DNA and are not reversible, the DNA methylation involves in addition of a methyl group to cytosine nucleotide to control genes expression which is reversible [1,2]. Methylation is unique change that consequence in different gene expression pattern and finally may trigger the onset of diseases like cancer [3]. Epigenetic reprogramming in cancer cells represents a unique methylation landscape concerning the net loss of global DNA methylation simultaneously with an increase in the levels of in CpGs islands. So, cancer epigenetically reprogrammed methylation landscape (i.e., Methylscape) can be a common feature exhibited by most cancer types and therefore can be a universal cancer biomarker. The DNA methylation in molecular level change the gene expression pattern of the cell but methylation can change the physicochemical properties of DNA polymer in solution including DNA structure and its affinity as well.

Introduction| References|


Online Submission System

Drag and drop files here


Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )